Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL696798 | 0.99 | TAAR1 (0.51) | TAAR1MEN1KMT2AMGLLMALT1 | |
| SCHEMBL19468009 | 0.88 | HDAC3 (0.52) | TAAR1MEN1KMT2AMGLLKDM4E | |
| Hydrochloric Acid SCHEMBL19468148 | 0.86 | HDAC3 (0.51) | TAAR1MEN1KMT2AMGLLKDM4E | |
| SCHEMBL20052592 | 0.86 | MEN1 (0.43) | TAAR1MEN1KMT2APTPN1LMNA | |
| SCHEMBL27752501 | 0.86 | NPC1 (0.50) | MEN1KMT2AKDM4ELMNANPC1 | |
| SCHEMBL15356006 | 0.85 | TAAR1 (0.49) | TAAR1MEN1KMT2AMGLLMALT1 | |
| SCHEMBL17540639 | 0.85 | SPR (0.46) | TAAR1MEN1KMT2AKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL27773440 | 0.84 | NPC1 (0.49) | MEN1KMT2AKDM4ELMNANPC1 | |
| SCHEMBL770890 | 0.80 | TAAR1 (0.73) | TAAR1MALT1GAAEPHX2HDAC3 | |
| SCHEMBL1351670 | 0.80 | SIGMAR1 (0.50) | TAAR1MEN1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243322-A1 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL AND INTERMEDIATES THEREFOR | ALIVIRA ANIMAL HEALTH LIMITED (IN) | 2025-11-27 | — | — | WO | claimed |
| US-8754215-B2 | Process for the preparation of praziquantel | SEQUENT SCIENTIFIC LIMITED (US) | 2014-06-17 | — | — | US | claimed |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-10-31 | — | — | US | claimed |
| EP-2651225-A2 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL | Sequent Scientific Limited (IN) | 2013-10-23 | — | — | EP | claimed |
| WO-2012081035-A2 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-06-21 | — | — | WO | claimed |
| WO-2025243322-A1 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL AND INTERMEDIATES THEREFOR | ALIVIRA ANIMAL HEALTH LIMITED (IN) | 2025-11-27 | — | — | WO | disclosed |
| WO-2021135891-A1 | PRAZIQUANTEL SYNTHESIS METHOD | 江苏诚信药业有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-8754215-B2 | Process for the preparation of praziquantel | SEQUENT SCIENTIFIC LIMITED (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754215-B2 | Process for the preparation of praziquantel | SEQUENT SCIENTIFIC LIMITED (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| WO-2012081035-A2 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-06-21 | — | — | WO | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| CN-101538222-A | Preparation method for N-(2-phenyl)ethyl-2-[(2,2-dimethoxyethyl)amino]acetamide halate | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-09-23 | — | — | CN | disclosed |
| CN-101538222-A | Preparation method for N-(2-phenyl)ethyl-2-[(2,2-dimethoxyethyl)amino]acetamide halate | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-09-23 | — | — | CN | disclosed |
| CN-101538223-A | Preparation method for N-(2-phenyl)ethyl-2-[(2,2-dimethoxyethyl)amino]acetamide halate | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-09-23 | — | — | CN | disclosed |
| CN-101538223-A | Preparation method for N-(2-phenyl)ethyl-2-[(2,2-dimethoxyethyl)amino]acetamide halate | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-09-23 | — | — | CN | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | TAAR1 805/4885MEN1 3362/4885KMT2A 701/4885 |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | CYP4B1, CYP2E1, CYP1A2 | TAAR1 3051/4885MEN1 4769/4885KMT2A 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.